The grant, stated plainly. On July 15, 2025, Nanjing GenScript Biotech was issued US12358987B2, covering an anti-CD47/anti-PD-1 bispecific antibody. The CPC tags — C07K 16/2818 (anti-PD-1), C07K 16/2803, A61P 35/00 (antineoplastic), plus the C07K 2317 engineering series — describe a construct that engages both the CD47 'don't eat me' signal and the PD-1 checkpoint.
Why a regulatory desk reads dual-checkpoint constructs: combining two checkpoint mechanisms in one molecule is a bet that the combination outperforms single-agent checkpoint blockade while simplifying dosing. The CD47 axis in particular has a complicated safety history, so the construct's design and the regulatory path are both load-bearing questions.
The disciplined read: a bispecific checkpoint construct grant is an exclusivity claim on a specific dual-targeting molecule, not a clinical or regulatory outcome. The stakes ride on whether dual engagement delivers a better benefit-risk profile in trials — answered by data and regulatory review, not the patent.
What the grant does not say: nothing about efficacy, safety signals, or approval, and nothing about freedom from competing checkpoint estates. Those are separate facts in separate records.
The takeaway: when tracking immuno-oncology catalysts, read dual-checkpoint construct grants for the specific combination bet each one makes. GenScript's July 2025 anti-CD47/anti-PD-1 grant is a dated example in the dual-checkpoint lane.